Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generic User Fees: FDA Reaches Out To More Trade Groups; Plan Could Mix Inspection and Application Fees

Executive Summary

FDA continues to mull inspection- and application-based proposals for a generic drug user fee, but before beginning negotiations it wants comments from a wider breadth of the industry.

You may also be interested in...



Generic User Fee Agreement Includes FDA Pledge To Determine Best Use Of Foreign Regulator Inspections

Draft commitment letter could be first step down globalization road in which FDA relies more on foreign governments to boost manufacturing oversight.

U.S. Generic User Fees Might Combine Inspection Visits, Boost Foreign Cooperation

U.S. FDA and the generic industry are considering ideas for combining inspections to reduce the number of visits from regulators as part of user fee discussions, while industry is concerned changes could affect cooperation with foreign entities

Generic User Fees Might Combine Inspection Visits, Boost Foreign Cooperation

Agency outlines ideas for coordinating and combining different types of facility inspections in generic drug user fee negotiations, while industry asks how it will affect collaboration with international regulators.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS052988

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel